Ep. 154 Why Biotech Startups Fail at Execution and How 3Helix Does It Differently episode artwork

EPISODE · Jan 23, 2026 · 31 MIN

Ep. 154 Why Biotech Startups Fail at Execution and How 3Helix Does It Differently

from Business Growth Spotlight · host Heidi Schalk

Show Notes:In this episode of Business Growth Spotlight, Heidi Schalk sits down with Toby from 3Helix to explore how biotech startups move from breakthrough science to real world commercialization. Toby shares his journey as an MD MBA leader navigating venture capital, startup strategy, and regulatory complexity while helping 3Helix pioneer extracellular matrix based therapies that target disease by changing the cellular environment.This conversation dives deep into startup strategy, physician leadership, go to market execution, and why credibility matters more than trying to do everything at once. It is a masterclass in how innovation, discipline, and strategic focus drive sustainable growth in highly regulated industries.Bio:Toby is a Physician, Investor, and Entrepreneur specializing in healthcare who works closely with early-stage teams leveraging broad networks and experience to help them minimize risk and maximize value. Toby brings a perspective drawn from his experience as a provider but also from his work with payers, investors, and Innovators. He was a member of Centene’s international division where he researched and implemented value based care initiatives in the Middle East, South America, the UK, and Southeast Asia, served in roles like Vice President of Business Development, Chief, Medical Officer, and Chief Operations Officer at start-ups across digital health, biotech, med device, gene therapy, and health tech, and has investing experience across angel, Venture, and private equity. He currently sits on the physician advisory boards of several Venture funds in the Chicago area in addition to being a founding partner at Syndicate Health Healthcare Operations Consulting. Toby holds an MD from Washington University in St. Louis and an MBA from Northwestern University’s Kellogg school of management.To connect with our guest, click on the links below:LinkedIn:   https://www.linkedin.com/in/toby-barrack-md-mba-5a1478104Website:  3Helix.comEmail:  [email protected] with me:LinkedIn:  https://www.linkedin.com/in/heidischalkcoaching/

Episode metadata supplied by the publisher feed · Published Jan 23, 2026

Embed this episode

Show Notes: In this episode of Business Growth Spotlight, Heidi Schalk sits down with Toby from 3Helix to explore how biotech startups move from breakthrough science to real world commercialization. Toby shares his journey as an MD MBA leader navigating venture capital, startup strategy, and regulatory complexity while helping 3Helix pioneer extracellular matrix based therapies that target disease by changing the cellular environment. This conversation dives deep into startup strategy, physic...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Ep. 154 Why Biotech Startups Fail at Execution and How 3Helix Does It Differently

0:00 31:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

Frequently Asked Questions

How long is this episode of Business Growth Spotlight?

This episode is 31 minutes long.

When was this Business Growth Spotlight episode published?

This episode was published on January 23, 2026.

Can I download this Business Growth Spotlight episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!